Uma Giri

Blasted Cell Line Names

Jeffrey N. Myers, John D. Minna, Li Shen, 2010, Cancer informatics.

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Michael Peyton, Li Shen, John N Weinstein, 2012, Cancer discovery.

Use of proteomic analysis of LKB1/AMPK/mTOR pathways to identify IGF-1R pathway upregulation with LKB1 loss or mTOR inhibition in NSCLC: Implications for targeted combinations.

John D. Minna, Kevin R. Coombes, Lixia Diao, 2012 .

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Michael Peyton, John D. Minna, Li Shen, 2012, Clinical Cancer Research.

Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.

Olivier Lichtarge, Marek Kimmel, Beth M Beadle, 2015, Cancer research.

Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.

Michael Peyton, Humam Kadara, Murim Choi, 2015, Cancer discovery.